Arvinas, Inc. vs Merck & Company, Inc. — Stock Comparison

ARVN
Arvinas, Inc.
$10.51
▲ 6.16%
vs
MRK
Merck & Company, Inc.
$112.16
▲ 2.73%
Q·Score Winner
Merck & Company, Inc.
MRK6.7/10vs 5/10

Q·Score Breakdown

5
Bearish
Overall
6.7
Neutral
0.8
Quality
6.2
9.2
Health
7
4.3
Growth
6.2
6.3
Valuation
7.2
5.9
Sentiment
7.1
ARVN

Clean balance sheet with low leverage (0.0× debt-to-equity).

currently unprofitable (-31% margin).

MRK

Forward P/E of 11.5× is low relative to sector peers.

Analyst Consensus

HOLD
Target $14.88 (+41.5%)
16 analysts
BUY
Target $129.74 (+15.7%)
27 analysts

Fundamentals

ARVN
MRK
Trailing P/E
31.5×
-3.0×
Forward P/E
11.5×
-30.8%
Profit Margin
13.6%
100.0%
Gross Margin
76.6%
-16.2%
ROE
-84.0%
Revenue Growth
4.9%
Earnings Growth
1.98
Beta
0.28
Price / Book
$672M
Market Cap
$277.0B
$6 – $15
52-Week Range
$73 – $125

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →